Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.99T
24h Vol:
$9.86B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  AMAM

Ambrx Biopharma Inc.

AMAM
55 / 100
High Growth
$27.91arrow_drop_down-0.10%-$0.03
Key Stats
Open$27.95
Prev. Close$27.94
EPS0.42
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.76B
PE Ratio66.52
LOWHIGH
Day Range27.94
28.03
52 Week Range4.69
28.15
Ratios
P/B Ratio7.29
Revenue$4.09M
Operating M. %-48,350.94%
Earnings$0.00
Earnings Growth %14.03%
EBITDA Margin %-1,000.00%
ROE %-37.23%
EPS0.42
Fundamentals
RPS$0.02
Gross Profit-
EBITDA-$61.74M
Total Debt$10.52M
P/S Ratio432.0x
Enterprise to EBITDA-22.17
Profit Margin0.00%
ROA-18.62%
Debt/Equity Ratio0.04%
Payout Ratio-
Industry average yield3.02%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

AMAMarrow_drop_down-0.11%
US Healthcare Sectorarrow_drop_up1.17%
US Marketarrow_drop_up0.46%
AMAM / Market
AMAM lose to the US Market which returned 0.46% over the last twenty four hours.
AMAM / Healthcare Sector
AMAM lose to the US Healthcare sector which returned 1.17% over the last twenty four hours.

Ambrx Biopharma Inc. (AMAM) Statistics

Ambrx Biopharma Inc. (AMAM) is a biopharmaceutical company that specializes in the development of novel protein therapeutics. The company focuses on the discovery and development of next-generation antibody-drug conjugates (ADCs), which are designed to selectively deliver potent payloads to target cells. AMAM stock statistics indicate that the company's shares have performed well in recent years, reflecting investor confidence in its innovative pipeline. The stock has consistently outperformed the broader sector, demonstrating the strength of AMAM's business model and the potential of its therapeutic candidates.

When it comes to valuation metrics, AMAM stands out as a promising investment opportunity. The company's fundamentals are strong, with robust revenue growth and a solid profit margin. AMAM stock's revenue per share has been steadily increasing, indicating that the company's top line is expanding. This growth is further supported by AMAM's impressive gross profit figures, which highlight the company's ability to generate revenue while efficiently managing its costs.

add Ambrx Biopharma Inc. to watchlist

Keep an eye on Ambrx Biopharma Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
How has Ambrx Biopharma Inc. (AMAM) stock's performance compared to its sector and the market over the past year?

Over the past year, Ambrx Biopharma Inc. (AMAM) has experienced a price change of 399.28%. Compared to the Healthcare sector, which saw a change of 33.58%, Ambrx Biopharma Inc. has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 40.25%, it has fallen short of the market average. This comparison highlights Ambrx Biopharma Inc.'s performance relative to both its sector and the overall market over the last year.

question_mark
What is the PE ratio of Ambrx Biopharma Inc. (AMAM) stock?

The PE (Price to Earnings) ratio of Ambrx Biopharma Inc. (AMAM) is currently 66.45. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

question_mark
What is the EPS of Ambrx Biopharma Inc. (AMAM) stock?

The Earnings Per Share (EPS) for Ambrx Biopharma Inc. (AMAM), calculated on a diluted basis, is $0.42. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

question_mark
What is the operating margin of Ambrx Biopharma Inc. (AMAM) stock?

The operating margin for Ambrx Biopharma Inc. (AMAM) is -48.35K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

question_mark
What is the EBITDA of Ambrx Biopharma Inc. (AMAM) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Ambrx Biopharma Inc. (AMAM) is -$61.75M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

question_mark
How much debt does Ambrx Biopharma Inc. (AMAM) have?

Ambrx Biopharma Inc. (AMAM) has a total debt of $10.52M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$214.74M.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.